BioSig Technologies, Inc. today announced that its subsidiary ViralClearP harmaceuticals, Inc. updated its clinical development program for Vicromax™ or merimepodib as a treatment for COVID-19.

The Phase II clinical trial will be conducted at Mayo Clinic under the leadership of Andrew D. Badley, M.D., Professor and Chair of Department of Molecular Medicine and the Enterprise Chair of COVID-19 Task Force.

“This trial is a part of our commitment to accelerate discoveries related to the SARS-CoV-2 virus and the disease it causes, COVID-19," says Andrew D. Badley, M.D., infectious disease expert, chair of the COVID-19 Research Task Force at Mayo Clinic.

“Evaluating efficacy of Vicromax ™ in patients is a top priority, and we are pleased that Mayo Clinic agreed to work with us on this critically important mission,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

“Over the past few weeks we worked very closely with Dr. Badley to understand the optimal mechanism of a trial which would not be disruptive to those on the frontline of the pandemic and would allow the industry to generate clinically relevant data. We are optimistic that Vicromax™ as a host-directed therapy will become a significant tool within the multi-faceted and rapidly-evolving COVID-19 standard of care,” commented Jerome Zeldis, M.D., Ph.D, Executive Chairman of ViralClear Pharmaceuticals, Inc.